SIGA Technologies, Inc.

NASDAQ•SIGA

執行長: Dr. Dennis E. Hruby Ph.D.

板塊: Healthcare

行業: Drug Manufacturers - Specialty & Generic

上市日期: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

聯絡資訊

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

市值

$404.60M

本益比 (TTM)

17.3

13.9

股息率

10.6%

52周最高

$9.62

52周最低

$4.95

52周範圍

15%

排名30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

基於 10 年期基本面

一般 • 5.1 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2016-2025

財務儀表板

Q4 2025 數據

營業收入

$3.80M+0.00%

近4季度走勢

每股收益

-$0.08+0.00%

近4季度走勢

自由現金流

-$11.30M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Net Income Decreased Sharply Net income for 2025 was $23.28M, a substantial decrease from $59.21M reported in the prior year period.

Total Revenues Fell Significantly Total revenues for 2025 totaled $94.57M, reflecting a significant contraction from $138.72M recorded in 2024.

Cash Position Remains Robust Cash and cash equivalents held steady at $155.0M at December 31, 2025, supporting liquidity needs for the near term.

BARDA Contract Execution Cumulative oral TPOXX® delivery value under the 19C BARDA Contract reached $450.2M as of December 31, 2025.

關注風險

Dependence on Government Contracts Substantial future revenue relies on U.S. Government commitment; failure to secure new contracts materially harms operations.

International Sales Dropped International sales sharply declined to $5.82M in 2025 from $23.0M in 2024, limiting diversification efforts.

EMA Mpox Authorization Review EMA CHMP referral on mpox effectiveness may recommend withdrawal, negatively impacting anticipated revenue streams.

Fixed Price Contract Exposure Fixed-price government contracts require absorbing cost overruns, potentially reducing profitability or causing material losses.

未來展望

Smallpox PEP Submission Targeted Targeting Supplemental NDA submission for oral TPOXX® smallpox PEP indication within the next twelve months based on trial results.

IV TPOXX Manufacturing Transition Actively transferring IV TPOXX® manufacturing process from Patheon to a new third-party site, requiring FDA approval.

Expanding International Sales Efforts Reacquired international promotional rights; building out internal sales organization to pursue recurring non-U.S. government sales.

同行對比

營業收入 (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$680.39M

+4.4%

毛利率 (最新季度)

CTMX

100.0%

+0.0pp

RIGL

91.5%

+7.7pp

KALV

91.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
OLMA	$1.24B	-9.0	-41.5%	1.3%
VTYX	$1.00B	-9.4	-48.1%	4.7%
KALV	$932.07M	-4.7	-282.0%	44.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-18.6%

增長承壓

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

50%

現金流需要關注

深度研究

下次財報:2026年5月6日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料